Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.95.

EBIT: As of FY2026 Q2, the actual value is USD -8.467 M.

The provided reference indicates that a press release announcing second-quarter financial results for the period ended June 30, 2026, was issued, but the actual content of this press release, which would contain specific segment revenue, gross margin, operating profit, operating margin, and cash flow data, is not included within the provided text, thus these specific metrics cannot be extracted from . However, other detailed operational metrics, balance sheet highlights, capital activities, and an outlook are available in the reference .

Operating Expenses

Total operating expenses for Atossa Therapeutics, Inc. were $8.7 million for the three months ended June 30, 2026, a decrease of $0.3 million from $9.0 million in the same period of 2025 . For the six months ended June 30, 2026, total operating expenses increased by $2.1 million to $18.6 million, compared to $16.5 million for the six months ended June 30, 2025 .

Research & Development (R&D) Expenses

Total R&D expenses were $4.9 million for the three months ended June 30, 2026, a decrease of -11% from $5.5 million in the prior year period . For the six months ended June 30, 2026, R&D expenses were $9.7 million, remaining relatively flat with a 0% change from $9.7 million in the prior year period . Clinical and non-clinical trials: These expenses decreased by -$0.6 million (-14%) to $3.5 million for the three months ended June 30, 2026, primarily due to a $1.0 million decrease in preclinical trials, partially offset by increases in clinical trial enrollment ($0.2 million) and drug development costs ($0.3 million) . For the six months ended June 30, 2026, these expenses increased by $0.4 million (6%) to $7.2 million, driven by a $1.5 million increase in clinical trial enrollments and a $0.7 million increase in drug development costs, partially offset by a $1.8 million decrease in preclinical work . Compensation: R&D compensation increased by $0.1 million (11%) to $954 thousand for the three months ended June 30, 2026, and by $0.2 million (9%) to $1.9 million for the six months ended June 30, 2026, primarily due to increases in non-cash stock-based compensation expense . Professional fees and other: These expenses decreased by -$0.1 million (-25%) to $418 thousand for the three months ended June 30, 2026, and by -$0.5 million (-50%) to $545 thousand for the six months ended June 30, 2026, mainly due to a decrease in regulatory consulting fees .

General and Administrative (G&A) Expenses

Total G&A expenses were $3.8 million for the three months ended June 30, 2026, an increase of 7% from $3.5 million in the prior year period . For the six months ended June 30, 2026, G&A expenses increased by 31% to $8.9 million, compared to $6.8 million in the prior year period . Compensation: G&A compensation decreased by -$0.3 million (-20%) to $1.2 million for the three months ended June 30, 2026, and by -$0.5 million (-15%) to $2.6 million for the six months ended June 30, 2026, primarily due to a decrease in headcount . Professional fees and other: These expenses increased by $0.6 million (29%) to $2.5 million for the three months ended June 30, 2026, and by $2.6 million (68%) to $6.3 million for the six months ended June 30, 2026, largely due to higher legal fees related to patent litigation and intellectual property management .

Operating Loss

Atossa Therapeutics, Inc. reported an operating loss of -$8.7 million for the three months ended June 30, 2026, compared to an operating loss of -$9.0 million for the same period in 2025 . For the six months ended June 30, 2026, the operating loss was -$18.6 million, compared to -$16.5 million for the six months ended June 30, 2025 .

Interest Income

Interest income was $0.2 million for the three months ended June 30, 2026, a decrease of -$0.4 million from $0.6 million in the prior year period . For the six months ended June 30, 2026, interest income was $0.5 million, a decrease of -$0.8 million from $1.4 million in the prior year period, primarily due to lower average cash balances .

Other Expense, Net

Other expense, net was -$24 thousand for the three months ended June 30, 2026, compared to -$28 thousand for the same period in 2025 . For the six months ended June 30, 2026, other expense, net was -$52 thousand, consistent with the prior year period .

Loss Before Income Taxes

Loss before income taxes was -$8.5 million for the three months ended June 30, 2026, compared to -$8.4 million for the same period in 2025 . For the six months ended June 30, 2026, loss before income taxes was -$18.1 million, compared to -$15.1 million for the six months ended June 30, 2025 .

Net Loss

Atossa Therapeutics, Inc. reported a net loss of -$8.5 million for the three months ended June 30, 2026, compared to -$8.4 million for the same period in 2025 . For the six months ended June 30, 2026, the net loss was -$18.1 million, compared to -$15.1 million for the six months ended June 30, 2025 .

Balance Sheet Highlights (as of June 30, 2026 vs. December 31, 2025)

• Cash and cash equivalents decreased to $26.1 million from $41.3 million .
• Total current assets decreased to $31.0 million from $45.6 million .
• Total assets decreased to $32.3 million from $47.6 million .
• Total current liabilities decreased to $5.5 million from $8.3 million .
• Total liabilities decreased to $5.5 million from $8.3 million .
• Total stockholders’ equity decreased to $26.8 million from $39.4 million .

Capital Activities

Atossa Therapeutics, Inc. strengthened its balance sheet by raising $4.5 million in upfront gross proceeds from a registered direct offering, with the potential for an additional $12 million from the full cash exercise of warrants . These funds are designated for clinical development of (Z)-endoxifen and general corporate working capital .

Outlook / Guidance

Atossa Therapeutics, Inc.’s 2026 outlook focuses on advancing the development and regulatory strategy for (Z)-endoxifen, exploring its potential in various indications, and strengthening its patent portfolio . The company may be eligible for a Priority Review Voucher (PRV) upon approval of a qualifying marketing application for (Z)-endoxifen for Rare Pediatric Disease (RPD), with past PRV sales ranging from $100 million to $220 million . However, the market value of a PRV is variable and subject to external factors .